JP2023549167A - ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 - Google Patents

ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Download PDF

Info

Publication number
JP2023549167A
JP2023549167A JP2023527966A JP2023527966A JP2023549167A JP 2023549167 A JP2023549167 A JP 2023549167A JP 2023527966 A JP2023527966 A JP 2023527966A JP 2023527966 A JP2023527966 A JP 2023527966A JP 2023549167 A JP2023549167 A JP 2023549167A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
fusion protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549167A5 (enExample
Inventor
ローブ，アンドレアス
ダブリュ． ホール，サミュエル
Original Assignee
フラックス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラックス セラピューティクス，インコーポレイテッド filed Critical フラックス セラピューティクス，インコーポレイテッド
Publication of JP2023549167A publication Critical patent/JP2023549167A/ja
Publication of JP2023549167A5 publication Critical patent/JP2023549167A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/19—Omega peptidases (3.4.19)
    • C12Y304/19012—Ubiquitinyl hydrolase 1 (3.4.19.12)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023527966A 2020-11-06 2021-11-05 ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Pending JP2023549167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110625P 2020-11-06 2020-11-06
US63/110,625 2020-11-06
PCT/US2021/058286 WO2022099034A2 (en) 2020-11-06 2021-11-05 Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023549167A true JP2023549167A (ja) 2023-11-22
JP2023549167A5 JP2023549167A5 (enExample) 2024-11-12

Family

ID=81458643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527966A Pending JP2023549167A (ja) 2020-11-06 2021-11-05 ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法

Country Status (7)

Country Link
US (1) US20240026330A1 (enExample)
EP (1) EP4240753A4 (enExample)
JP (1) JP2023549167A (enExample)
CN (1) CN116802199A (enExample)
AU (1) AU2021376278A1 (enExample)
CA (1) CA3200982A1 (enExample)
WO (1) WO2022099034A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115998769B (zh) * 2022-11-02 2025-12-09 中国人民解放军军事科学院军事医学研究院 以Mysm1基因为抑制靶标的物质在提高线粒体活性中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200263159A1 (en) * 2017-11-06 2020-08-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes
WO2020169650A1 (en) * 2019-02-21 2020-08-27 Locki Therapeutics Limited Survival-targeting chimeric (surtac) molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012177549A (ja) * 2009-06-24 2012-09-13 Hokkaido Univ 蛍光温度プローブおよびそれを用いた温度測定装置
US20210079366A1 (en) * 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200263159A1 (en) * 2017-11-06 2020-08-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes
WO2020169650A1 (en) * 2019-02-21 2020-08-27 Locki Therapeutics Limited Survival-targeting chimeric (surtac) molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CELL REPORTS, vol. 23, JPN6025050997, 2018, pages 2852 - 2863, ISSN: 0005753931 *

Also Published As

Publication number Publication date
US20240026330A1 (en) 2024-01-25
CN116802199A (zh) 2023-09-22
EP4240753A2 (en) 2023-09-13
AU2021376278A1 (en) 2023-06-08
CA3200982A1 (en) 2022-05-12
WO2022099034A2 (en) 2022-05-12
WO2022099034A3 (en) 2022-06-09
EP4240753A4 (en) 2024-08-28
AU2021376278A9 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
CN105579471B (zh) 结合人程序性死亡配体1(pd-l1)的抗体
CN116113439A (zh) 抗ceacam5抗体和缀合物及其用途
US12168696B2 (en) Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
CN117597364A (zh) 抗ccr8抗体、其抗原结合片段、以及试剂和组合物及其制备和使用方法
US20250179210A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
JP2023549761A (ja) 核タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
US12043669B2 (en) IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof
JP2023549167A (ja) ミトコンドリアタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
JP2023548973A (ja) 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
US11802151B2 (en) Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
WO2022093641A1 (en) Anti-nkg2a agents and compositions and methods for making and using the same
JP2023551068A (ja) サイトゾルタンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法
US20250197507A1 (en) Cd161 binding proteins and related methods
EP4293046A1 (en) Anti-pd-1 antibody and use thereof
WO2022182562A1 (en) ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
EP4558523A1 (en) Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2025096542A2 (en) Clec2d binding proteins and related methods
TW202513590A (zh) 與ｌｉｌｒｂ１結合的抗體或抗原結合片段及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406